EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, U2Bio Co's enterprise value is ₩15,287 Mil.
U2Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩993 Mil. Therefore, U2Bio Co's EV-to-EBITDA for today is 15.39.
The historical rank and industry rank for U2Bio Co's EV-to-EBITDA or its related term are showing as below:
XKRX:221800'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -45.85 Med: 23.95 Max: 229.48
Current: 15.39
During the past 9 years, the highest EV-to-EBITDA of U2Bio Co was 229.48. The lowest was -45.85. And the median was 23.95.
XKRX:221800's EV-to-EBITDA is ranked better than 54.87% of 113
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.37
vs XKRX:221800: 15.39
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-26), U2Bio Co's stock price is ₩4500.00.
U2Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩63.000. Therefore, U2Bio Co's PE Ratio for today is 71.43.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
U2Bio Co EV-to-EBITDA Historical Data
The historical data trend for U2Bio Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, U2Bio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
U2Bio Co's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, U2Bio Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where U2Bio Co's EV-to-EBITDA falls into.
U2Bio Co EV-to-EBITDA Calculation
U2Bio Co's EV-to-EBITDA for today is calculated as:
U2Bio Co's current Enterprise Value is ₩15,287 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U2Bio Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩993 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
U2Bio Co (XKRX:221800) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
U2Bio Co's share price for today is ₩4500.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. U2Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩63.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of U2Bio Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
U2Bio Co Ltd provides vitro diagnostic test services. The company is engaged in offering general diagnostic tests, molecular diagnostic tests, and breastfeeding nutritional analysis services among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:221800 has been successfully added to your 